Catalyst Pharmaceuticals, Inc. · BOATS:CPRX

Catalyst Pharmaceuticals, Inc. financial statements

Catalyst Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue589.0M491.7M398.2M214.2M140.8M119.1M102.3M500.0K00
Cost of revenue87.3M68.8M52.0M34.4M21.9M17.0M14.8M19.9M45.7K43.4K
Gross profit501.7M422.9M346.2M179.8M118.9M102.0M87.5M500.0K-45.7K-43.4K
Research and development12.7M12.6M93.2M19.8M16.9M16.5M18.8M19.9M11.4M11.4M
Selling, general and administrative71.5M167.7M47.0M28.7M23.5M20.7M36.9M15.9M7.30M7.91M
Operating income257.8M195.1M86.8M101.8M52.4M41.3M31.8M-35.3M-18.7M-19.3M
Depreciation and amortization37.9M37.8M32.9M1.24M192.0K885.3K297.7K38.0K45.7K43.4K
EBITDA295.7M232.9M119.7M103.1M52.6M42.2M32.1M-35.3M-18.6M-19.2M
Interest expense4.12M474.0K1.47M1.88M1.29M454.2K321.6K
Income before tax283.5M216.3M94.5M104.7M52.7M41.9M33.4M-34.0M-18.4M-18.1M
Income tax69.2M52.4M23.1M21.6M13.2M-33.1M1.53M2.58M141.2K-929.5K
Net income214.3M163.9M71.4M83.1M39.5M75.0M31.9M-34.0M-18.4M-18.1M
Earnings per share, basic1.681.310.630.750.370.710.30-0.33-0.21-0.22

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents709.2M517.6M137.6M298.4M171.4M130.2M89.5M16.6M57.5M13.9M
Short-term investments019.8M10.0M5.01M36.9M26.5M26.5M
Receivables128.3M65.5M53.5M10.8M6.72M5.99M10.5M
Inventory37.2M19.5M15.6M6.80M7.87M4.65M1.96M56.0K00
Current assets894.0M623.6M219.3M320.8M210.1M159.2M111.4M55.2M85.2M41.5M
Property, plant and equipment847.0K3.98M129.8K210.5K245.4K191.4K244.2K
Goodwill00
Total assets1.11B851.4M470.1M375.6M237.8M192.4M112.4M60.4M85.4M41.7M
Accounts payable11.2M16.6M14.8M3.98M2.77M4.26M4.12M2.34M1.95M933.2K
Current liabilities147.2M120.7M76.1M57.6M27.1M22.8M24.1M9.51M4.27M2.09M
Long-term debt00
Total debt2.79M3.19M3.56M3.89M4.20M29.0K948.0K
Total liabilities152.5M123.8M82.2M75.2M31.0M22.8M24.7M9.67M4.42M2.40M
Shareholders' equity954.3M727.6M387.9M300.4M206.8M169.6M87.6M50.8M81.0M39.3M
Shares outstanding127.3M124.9M113.8M111.4M107.8M106.2M106.0M102.6M85.8M82.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations208.7M239.8M143.6M116.0M60.4M45.0M34.6M-25.7M-13.7M-18.0M
Capital spending-58.0K-556.0K-81.7M-29.0K-1.02M-11.4K-19.4K-92.0K-92.0K-96.1K
Free cash flow208.6M239.3M61.9M116.0M59.4M45.0M34.6M-25.8M-13.7M-18.1M
Cash from investing-58.0K-556.0K-293.5M9.21M-11.0M-5.01M37.2M-15.5M-3.96K3.55M
Cash from financing-17.0M140.7M-10.9M1.69M-8.14M701.9K1.12M293.1K57.4M69.0K
Dividends paid00
Share buybacks-25.3M-296.0K-982.0K-6.91M-12.1M-56.0K1.12M-4.45K57.4M-11.3K
Change in cash191.6M379.9M-160.8M127.0M41.2M40.7M73.0M-40.9M43.6M-14.3M